Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs

Background: The MEK (mitogen-activated protein kinase)–inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC). We aimed to analyse the effect of selumetinib on the expression of so...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Wächter, Sabine, Wunderlich, Annette, Greene, Brandon H., Roth, Silvia, Elxnat, Moritz, Fellinger, Sebastian A., Verburg, Frederik A., Luster, Markus, Bartsch, Detlef K., Di Fazio, Pietro
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073679/
https://ncbi.nlm.nih.gov/pubmed/30018229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19072077
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados